Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets cut its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 44.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 221,739 shares of the company's stock after selling 173,956 shares during the period. BNP Paribas Financial Markets owned 0.48% of Pacira BioSciences worth $4,178,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Sterling Capital Management LLC raised its position in shares of Pacira BioSciences by 779.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,363 shares of the company's stock worth $26,000 after purchasing an additional 1,208 shares during the period. Ancora Advisors LLC bought a new position in Pacira BioSciences during the 4th quarter worth $26,000. Caitlin John LLC raised its holdings in Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company's stock valued at $35,000 after acquiring an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after buying an additional 2,749 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Pacira BioSciences by 16.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company's stock valued at $68,000 after purchasing an additional 513 shares during the last quarter. Institutional investors own 99.73% of the company's stock.

Pacira BioSciences Price Performance

PCRX stock traded down $0.06 during mid-day trading on Tuesday, reaching $26.09. The company's stock had a trading volume of 79,437 shares, compared to its average volume of 968,331. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The company's 50 day moving average is $24.96 and its two-hundred day moving average is $22.51. The stock has a market cap of $1.21 billion, a PE ratio of -12.87 and a beta of 0.56. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.64.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. Truist Financial upgraded shares of Pacira BioSciences from a "sell" rating to a "hold" rating and lifted their price objective for the company from $8.00 to $25.00 in a report on Thursday, January 30th. Barclays lifted their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. HC Wainwright lifted their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a report on Tuesday, April 8th. Finally, Needham & Company LLC lowered their price target on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Friday, May 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat.com, Pacira BioSciences presently has a consensus rating of "Hold" and an average target price of $26.44.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.